Furiex Pharmaceuticals, Inc. 4
4 · Furiex Pharmaceuticals, Inc. · Filed Sep 12, 2013
Insider Transaction Report
Form 4
COVINGTON PAUL S
Senior VP-Clinical Operations
Transactions
- Exercise/Conversion
Common Stock
2013-09-10$9.11/sh+30,000$273,300→ 45,123 total - Exercise/Conversion
Stock Options (to buy)
2013-09-10−30,000→ 45,691 totalExercise: $9.11Exp: 2020-06-17→ Common Stock (30,000 underlying) - Sale
Common Stock
2013-09-10$40.89/sh−30,000$1,226,700→ 15,123 total
Holdings
- 26,000
Stock Options (to buy)
Exercise: $15.00Exp: 2021-05-09→ Common Stock (26,000 underlying) - 37,944
Stock Options (to buy)
Exercise: $13.16Exp: 2021-10-03→ Common Stock (37,944 underlying) - 10,368
Stock Options (to buy)
Exercise: $17.80Exp: 2022-02-24→ Common Stock (10,368 underlying)
Footnotes (4)
- [F1]The options were awarded on 6/17/2010 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
- [F2]The options were awarded on 5/9/2011. One-third of the options vest on the date of grant and the remaining two-thirds vest in two equal annual installments on the first and second anniversaries of the date of grant, provided the Optionee's employment continues.
- [F3]The options were awarded on 10/3/2011 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
- [F4]The options were awarded on 2/24/2012 and vest over three years, with one-third vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.